Skip to content

The efficacy and safety of antiemetic therapy for carboplatin-containing chemotherapy-induced nausea and vomiting in patients with lung cancer.

The efficacy and safety of antiemetic therapy for carboplatin-containing chemotherapy-induced nausea and vomiting in patients with lung cancer. - Antiemetic therapy for carboplatin-containing chemotherapy-induced nausea and vomiting.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000026739
Enrollment
30
Registered
2017-04-01
Start date
2017-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced lung cancer

Interventions

aprepitant, 5-HT3 receptor antagonist, dexamethasone, olanzapine

Sponsors

Second Division, Department of Internal Medicine, Hamamatsu university school of medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)advanced lung cancer patients who receive carboplatin containing chemotherapy 2)20 years old or older. 3)performance status 0-2. 4)written informed consent.

Exclusion criteria

Exclusion criteria: 1)patients with the history of hypersensitivity or allergy for study drugs. 2)patients who need and use antiemetic therapy during 48h before chemotherapy. 3)patients with severe hepatic or renal dysfunction. 4)With convulsion. 5)Patients who need puncture to manage ascites. 6)Patients with complications inducing nausea and vomiting. 7)Patients with diabetes mellitus. 8)Patients who are judged to be inappropriate for this study.

Design outcomes

Primary

MeasureTime frame
Complete response rate during the 120 h after carboplatin administration.

Secondary

MeasureTime frame
Complete response rate during the acute, delayed phase. Complete control rate, safety.

Countries

Japan

Contacts

Public ContactKazuki Tanaka

Hamamatsu university school of medicine Second Division, Department of Internal Medicine

41231644@hama-med.ac.jp053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026